Recurrent Anaplastic Large Cell Lymphoma: Clinical Trials

7 trials for Recurrent Anaplastic Large Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 1 active not recruiting. 7 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 3, Terminated 3, Active not recruiting 1
Phase 14Completed 3, Active not recruiting 1

Follow Recurrent Anaplastic Large Cell Lymphoma: new trials by email Literature Review of Recurrent Anaplastic Large Cell Lymphoma trials Research Report on Recurrent Anaplastic Large Cell Lymphoma

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center452020-07-182026-09-30
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Phase 1 / Phase 2Active not recruitingCity of Hope Medical Center132019-02-252026-10-29
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center382017-11-142026-11-16
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma
Phase 2TerminatedMayo Clinic122017-05-172020-04-21
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Onalespib - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2TerminatedNational Cancer Institute (NCI)252016-04-042022-09-13
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission
Phase 2TerminatedFred Hutchinson Cancer Center462010-05-192023-01-23
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma
Phase 1 / Phase 2CompletedUniversity of Nebraska742009-11-122023-10-10

Narrower conditions

Lymphoma, Large-Cell, Anaplastic (7)  ·  Lymphoma, T-Cell (4)  ·  Mycosis Fungoides (4)  ·  Immunoblastic Lymphadenopathy (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Enteropathy-Associated T-Cell Lymphoma (2)  ·  Lymphoma, Follicular (2)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Burkitt Lymphoma (1)  ·  HTLV-I Infections (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)

Broader conditions

Hemic and Lymphatic Diseases (7)  ·  Immune System Diseases (7)  ·  Immunoproliferative Disorders (7)  ·  Lymphatic Diseases (7)  ·  Lymphoma (7)  ·  Lymphoproliferative Disorders (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Lymphoma, Non-Hodgkin (6)  ·  Lymphadenopathy (3)  ·  Lymphoma, T-Cell (3)  ·  Lymphoma, T-Cell, Cutaneous (3)  ·  Hematologic Diseases (2)  ·  Infections (2)  ·  Leukemia (2)

Interventions

Cyclophosphamide (2)  ·  fludarabine phosphate (2)  ·  pembrolizumab (2)  ·  (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1)  ·  10-propargyl-10-deazaaminopterin (1)  ·  AFM13 (1)  ·  CT-P10 (1)  ·  Carmustine (1)  ·  Cytarabine (1)  ·  Depsipeptides (1)  ·  Etoposide (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Lactones (1)  ·  Lenalidomide (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  City of Hope Medical Center (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Mayo Clinic (1)  ·  National Cancer Institute (NCI) (1)  ·  University of Nebraska (1)

Countries

United States (7)

Top investigators

Alex F Herrera (1)  ·  Caron A Jacobson (1)  ·  Julie Vose, MD, MBA (1)  ·  Rachel B. Salit (1)  ·  Stephen Ansell (1)  ·  Swaminathan P Iyer, MD (1)  ·  Yago L Nieto (1)

Results publications

PMID 23834234, PMID 35750419, PMID 40186077

NIH funding

P30CA015083 (1), P30CA036727 (1), UM1CA186690 (1), UM1CA186709 (1)